Your browser doesn't support javascript.
loading
Surgical resection for large hepatocellular carcinoma and those beyond BCLC: systematic review with proposed management algorithm.
Pandrowala, Saneya; Patkar, Shraddha; Goel, Mahesh; Mirza, Darius; Mathur, S K.
Afiliação
  • Pandrowala S; Gastrointestinal and Hepato-Pancreato-Biliary Service, Department of Surgical Oncology, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India.
  • Patkar S; Gastrointestinal and Hepato-Pancreato-Biliary Service, Department of Surgical Oncology, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India.
  • Goel M; Gastrointestinal and Hepato-Pancreato-Biliary Service, Department of Surgical Oncology, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, India. drmaheshgoel@gmail.com.
  • Mirza D; Hepato-Pancreato-Biliary and Transplant Surgery, University Hospital Birmingham and Birmingham Children's Hospital, Birmingham, UK.
  • Mathur SK; Zen Digestive Disease Center, Zen Hospital, Mumbai, India.
Langenbecks Arch Surg ; 408(1): 144, 2023 Apr 12.
Article em En | MEDLINE | ID: mdl-37041364
ABSTRACT

BACKGROUND:

Hepatocellular carcinoma (HCC) accounts for the sixth most common cancer and ranks third in mortality worldwide with inhomogeneity in terms of resection for advanced-stage disease.

METHODS:

A systematic review of published literature using the PubMed, Medline, and Google Scholar databases from 1995 to 2020 was conducted to identify studies that reported outcomes of resection for solitary HCC > 10 cm, BCLC B/C, and multinodular HCC. Our aim was to assess overall survival for resection, identify poor prognostic factors, and to compare it to trans-arterial chemotherapy (TACE) where data was available.

RESULTS:

Eighty-nine articles were included after a complete database search in the systematic review as per our predefined criteria. Analysis revealed a 5-year overall survival of 33.5% for resection of HCC > 10 cm, 41.7% for BCLC B, 23.3% for BCLC C, and 36.6% for multinodular HCC. Peri-operative mortality ranged from 0 to 6.9%. Studies comparing resection versus TACE for BCLC B/C had a survival of 40% versus 17%, respectively.

CONCLUSION:

Our systematic review justifies hepatic resection wherever feasible for hepatocellular carcinomas > 10 cm, BCLC B, BCLC C, and multinodular tumors. In addition, we identified and proposed an algorithm with five poor prognostic criteria in this group of patients who may benefit from adjuvant TACE.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quimioembolização Terapêutica / Carcinoma Hepatocelular / Neoplasias Hepáticas Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quimioembolização Terapêutica / Carcinoma Hepatocelular / Neoplasias Hepáticas Idioma: En Ano de publicação: 2023 Tipo de documento: Article